Stock Events

Stock Events

Defiance AI & Power Infrastructure UCITS 

$6.67
179
+$0.18+2.85%Friday 16:29

Statistics

Day High
6.75
Day Low
6.49
52W High
10.28
52W Low
6.28
Volume
71,022.98
Avg. Volume
-
Mkt Cap
140.31M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Expense Ratio

0.69%
0%
1%+
The annual fee that you pay to the fund company for managing your investment. The lower the expense ratio, the better. This is not an investment recommendation.

Earnings

Nov 16Expected
Q2 2026
Next
-0.91
-0.65
-0.39
-0.13
Expected EPS
-0.15
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AIPO.LSE. It's not an investment recommendation.
NVIDIA
15
NVDA
Microsoft
14
MSFT
Amazon
14
AMZN
Alphabet
14
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Amarin
AMRN
Mkt Cap509.13M
Amarin Corporation plc focuses on the development and commercialization of therapeutics for cardiovascular health, directly competing with Acasti Pharma's focus on omega-3 phospholipids for similar conditions.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca PLC, a large pharmaceutical company, has a diverse portfolio that includes treatments for cardiovascular diseases, competing with Acasti Pharma's cardiovascular focus.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. has a broad range of products including treatments for cardiovascular diseases, making it a competitor to Acasti Pharma in the cardiovascular therapeutic area.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. offers a wide range of healthcare solutions, including cardiovascular disease treatments, competing with Acasti Pharma's product offerings.
Novartis
NVS
Mkt Cap303.67B
Novartis AG, with its extensive research and development in cardiovascular diseases, competes with Acasti Pharma in the market for cardiovascular health solutions.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline plc has a diversified portfolio that includes cardiovascular drugs, making it a competitor to Acasti Pharma in the cardiovascular space.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie Inc. engages in the discovery, development, manufacture, and sale of a broad line of pharmaceuticals, including those for cardiovascular diseases, competing with Acasti Pharma.
AMGEN
AMGN
Mkt Cap251.94B
Amgen Inc. focuses on human therapeutics, including cardiovascular disease treatments, which positions it as a competitor to Acasti Pharma.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol-Myers Squibb Company offers a wide range of prescription pharmaceuticals in several therapeutic areas, including cardiovascular diseases, competing with Acasti Pharma's focus.

Holdings

Regions

Sectors

About

Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Show More
CEO
Prashant Kohli
Employees
5
Country
United States
ISIN
IE000WUTBLT5
WKN
000A423YD

Listings

F
DE
A1P0.F
MI
IT
AIPO.MI
XETRA
DE
A1P0.XETRA
STU
DE
L8S.STU

0 Comments

Share your thoughts

FAQs

What is Defiance AI & Power Infrastructure UCITS stock price today?▼
The current price of AIPO.LSE is $6.67 USD — it has increased by +2.85% in the past 24 hours. Watch Defiance AI & Power Infrastructure UCITS stock price performance more closely on the chart.
What is Defiance AI & Power Infrastructure UCITS stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on London Exchange exchange Defiance AI & Power Infrastructure UCITS stocks are traded under the ticker AIPO.LSE.
What is Defiance AI & Power Infrastructure UCITS market cap?▼
Today Defiance AI & Power Infrastructure UCITS has the market capitalization of 140.31M
When is the next Defiance AI & Power Infrastructure UCITS earnings date?▼
Defiance AI & Power Infrastructure UCITS is going to release the next earnings report on November 16, 2026.
What were Defiance AI & Power Infrastructure UCITS earnings last quarter?▼
AIPO.LSE earnings for the last quarter are -0.91 USD per share, whereas the estimation was -0.13 USD resulting in a -603.79% surprise. The estimated earnings for the next quarter are N/A USD per share.
How many employees does Defiance AI & Power Infrastructure UCITS have?▼
As of November 7, 2026, the company has 5 employees.
In which sector is Defiance AI & Power Infrastructure UCITS located?▼
Defiance AI & Power Infrastructure UCITS operates in the Health & Wellness sector.
When did Defiance AI & Power Infrastructure UCITS complete a stock split?▼
Defiance AI & Power Infrastructure UCITS has not had any recent stock splits.
Where is Defiance AI & Power Infrastructure UCITS headquartered?▼
Defiance AI & Power Infrastructure UCITS is headquartered in PRINCETON, United States.